CN Patent

CN1173926C — 经取代的2-苯基-1-(3,4-二羟基-5-硝基苯基)-1-乙烷酮类化合物、其在治疗一些中枢神经和周围神经系统疾病中的应用以及包含这些化合物的药物组合物

Assigned to Portela & Ca S A · Expires 2004-11-03 · 22y expired

What this patent protects

本发明描述了式(I)的新型化合物：该化合物在治疗一些中枢和周围神经系统疾病中具有强的有价值的药物性质，其中减少儿茶酚胺的O-甲基化对该疾病具有治疗益处，所述疾病例如是帕金森病和帕金森机能障碍、胃肠道紊乱、浮肿形成病态和高血压。

USPTO Abstract

本发明描述了式(I)的新型化合物：该化合物在治疗一些中枢和周围神经系统疾病中具有强的有价值的药物性质，其中减少儿茶酚胺的O-甲基化对该疾病具有治疗益处，所述疾病例如是帕金森病和帕金森机能障碍、胃肠道紊乱、浮肿形成病态和高血压。

Drugs covered by this patent

Patent Metadata

Patent number: CN1173926C
Jurisdiction: CN
Classification: —
Expires: 2004-11-03
Drug substance claim: No
Drug product claim: No
Assignee: Portela & Ca S A
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.